<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Survivin is a member of the inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> protein (IAPs) family and considered to play a pivotal role in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We present the first report of survivin expression profile in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Expression of survivin <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> was evaluated by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Eleven out of 12 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) (91.6%), and <z:hpo ids='HP_0000001'>all</z:hpo> 3 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (RAEBt) (100%), were positive for survivin expression with the majority of cases showing abundant levels of the survivin transcript </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, expression of survivin was undetectable in the 4 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) </plain></SENT>
<SENT sid="5" pm="."><plain>The level and frequency of survivin expression in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> were compared to those in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Out of 12 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 5 patients (41.7%) showed detectable levels of survivin expression </plain></SENT>
<SENT sid="7" pm="."><plain>Abundant survivin expression in RA was also confirmed by immunohistochemistry </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, survivin was almost absent in two cases with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>We propose that high levels of survivin expression can serve as a reliable diagnostic marker of RA in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>